Background/Aims: Previous studies indicate that patients with the parkinsonian subtype of multiple system atrophy (MSA-P) experience cognitive impairment. This study aimed to identify the existence of cognitive impairments and the different topographic patterns of morphological changes in MSA-P by means of imaging analysis, and also whether these morphological changes could be associated with cognitive dysfunctions in MSA-P. Methods: We recruited 15 nondemented probable MSA-P patients and 32 normal controls (NC) for neuropsychological testing and MRI. We analyzed morphological changes using cortical thickness analysis, voxel-based morphometry (VBM) and cerebellar volumetry. Multiple linear regression analysis was performed to evaluate the correlation of each cognitive score with the mean thickness of significant cortical-thinning clusters, mean gray-matter density of VBM clusters and cerebellar volume. Results: The scores on the Digit Span Test, the Seoul Verbal Learning Test (immediate and delayed), the phonemic Controlled Oral Word Association Test and the Stroop color test were significantly lower in the MSA-P group than in the NC group. We found two clusters exhibiting significant cortical thinning in the right paracentral lobule and parahippocampal gyrus. VBM analysis revealed significant gray-matter atrophy in the MSA-P group in the bilateral basal ganglia, cerebellum and temporal and frontal cortical areas. Multiple linear regression analysis demonstrated that cognitive dysfunction correlated significantly with thinning in the neocortex, cerebellum and striatum. Conclusions: Our data demonstrate that cortical and cerebellar atrophy and striatal degeneration are associated with cognitive impairment in patients with MSA-P.

Keywords:
Neuroimaging, Cortical thickness, Multiple system atrophy, Cognitive impairment, Voxel-based morphometry
1.
Trojanowski JQ, Revesz T: Proposed neuropathological criteria for the postmortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007;33:615-620.
2.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
3.
Pillon B, Gouider-Khouja N, Deweer B, Vidailhet M, Malapani C, Dubois B, Agid Y: Neuropsychological pattern of striatonigral degeneration Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1995;58:174-179.
4.
Robbins T, James M, Owen A, Lange K, Lees A, Leigh PN, Marsden CD, Quinn N, Summers BA: Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57:79-88.
5.
Burk K, Daum I, Rub U: Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 2006;21:772-776.
6.
Hong HJ, Song SK, Lee PH, Sohn YH, Lee JE: Cognitive impairments in multiple system atrophy of the cerebellar type. J Mov Disord 2011;4:41-45.
7.
Chang CC, Chang YY, Chang WN, Lee YC, Wang YL, Lui CC, Huang CW, Liu WL: Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol 2009;16:1144-1150.
8.
Tir M, Delmaire C, le Thuc V, Duhamel A, Destee A, Pruvo JP, Defebvre L: Motor-related circuit dysfunction in MSA-P: usefulness of combined whole-brain imaging analysis. Mov Disord 2009;24:863-870.
9.
Kim JS, Youn J, Yang JJ, Lee DK, Lee JM, Kim ST, Kim HT, Cho JW: Topographic distribution of cortical thinning in subtypes of multiple system atrophy. Parkinsonism Relat Disord 2013;19:970-974.
10.
Kawai Y, Suenaga M, Takeda A, Ito M, Watanabe H, Tanaka F, Kato K, Fukatsu H, Naganawa S, Kato T, Ito K, Sobue G: Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008;70:1390-1396.
11.
Kang Y, Na DL: Seoul Neuropsychological Screening Battery. Incheon, Human Brain Research & Consulting Co., 2003.
12.
Kang Y, Na DL, Hahn S: A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.
13.
Kim H, Na DL: Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol 1999;21:127-133.
14.
Dujardin K, Defebvre L, Krystkowiak P, Degreef JF, Destee A: Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 2003;9:205-211.
15.
Lange KW, Tucha O, Alders GL, Preier M, Csoti I, Merz B, Mark G, Herting B, Fornadi F, Reichmann H, Vieregge P, Reiners K, Becker G, Naumann M: Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm 2003;110:983-995.
16.
Meco G, Gasparini M, Doricchi F: Attentional functions in multiple system atrophy and Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;60:393-398.
17.
Lee JY, Dong Woo L, Cho SJ, Na DL, Hong Jin J, Kim SK, You Ra L, Youn JH, Kwon M, Lee JH, Maeng Je C: Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008;21:104-110.
18.
Zijdenbos AP, Forghani R, Evans AC: Automatic ‘pipeline' analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging 2002;21:1280-1291.
19.
Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, James S, Voets N, Watkins K, Matthews PM, James A: Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007;130:2375-2386.
20.
Smith SM, Nichols TE: Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83-98.
21.
Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, Gurevich T, Balas M, Giladi N, Santacruz P, Marti F, Tolosa E, Rubino A, Meco G, Poewe W, Pezzoli G, Wenning G, Antonini A: A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm 2013;120:613-618.
22.
Balas M, Balash Y, Giladi N, Gurevich T: Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. J Neural Transm 2010;117:369-375.
23.
Robbins T, James M, Lange K, Owen A, Quinn N, Marsden C: Cognitive performance in multiple system atrophy. Brain 1992;115:271-291.
24.
Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG: Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008;64:239-246.
25.
Wakabayashi K, Ikeuchi T, Ishikawa A, Takahashi H: Multiple system atrophy with severe involvement of the motor cortical areas and cerebral white matter. J Neurol Sci 1998;156:114-117.
26.
Su M, Yoshida Y, Hirata Y, Watahiki Y, Nagata K: Primary involvement of the motor area in association with nigrostriatal pathway in MSA: neuropathological and morphometric evaluations. Acta Neuropathol 2001;101:57-64.
27.
Brenneis C, Egger K, Scherfler C, Seppi K, Schocke M, Poewe W, Wenning GK: Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol 2007;254:191-196.
28.
Brenneis C, Seppi K, Schocke MF, Muller J, Luginger E, Bosch S, Loscher WN, Buchel C, Poewe W, Wenning GK: Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord 2003;18:1132-1138.
29.
Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Kostic VS, Ling H, Meissner WG, Poewe W, Semnic M, Seppi K, Takeda A, Weintraub D, Wenning GK: Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 2014;29:857-867.
30.
Brown R, Marsden C: ‘Subcortical dementia': the neuropsychological evidence. Neuroscience 1988;25:363-387.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.